Brain, Vol. 125, No. 7, 1450-1461,
July 2002
© 2002 Guarantors of Brain
A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica
Departments of 1 Neurology, 2 Immunology and 3 Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 4 Department of Neurology, George Washington University, Washington, DC, 5 Department of Neurosciences of The Lerner Research Institute and Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, 6 Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA, 7 Brain Research Institute, Vienna, Austria and 8 Department of Neuropathology, Charite, Berlin, Germany
Correspondence to: Claudia F. Lucchinetti, Associate Professor of Neurology, Mayo Clinic, Rochester, MN, USA E-mail: lucchinetti.claudia{at}mayo.edu
Received October 9, 2001. Revised January 15, 2002. Accepted February 14, 2002.
 |
Summary |
|---|
 Top Summary IntroductionMaterial and methodsResultsDiscussionReferences |
|---|
Devic’s disease [neuromyelitis optica (NMO)] is an idiopathic inflammatory demyelinating disease of the CNS, characterized by attacks of optic neuritis and myelitis. The mechanisms that result in selective localization of inflammatory demyelinating lesions to the optic nerves and spinal cord are unknown. Serological and clinical evidence of B cell autoimmunity has been observed in a high proportion of patients with NMO. The purpose of this study was to investigate the importance of humoral mechanisms, including complement activation, in producing the necrotizing demyelination seen in the spinal cord and optic nerves. Eighty-two lesions were examined from nine autopsy cases of clinically confirmed Devic’s disease. Demyelinating activity in the lesions was immunocytochemically classified as early active (21 lesions), late active (18 lesions), inactive (35 lesions) or remyelinating (eight lesions) by examining the antigenic profile of myelin degradation products within macrophages. The pathology of the lesions was analysed using a broad spectrum of immunological and neurobiological markers, and lesions were defined on the basis of myelin protein loss, the geography and extension of plaques, the patterns of oligodendrocyte destruction and the immunopathological evidence of complement activation. The pathology was identical in all nine patients. Extensive demyelination was present across multiple spinal cord levels, associated with cavitation, necrosis and acute axonal pathology (spheroids), in both grey and white matter. There was a pronounced loss of oligodendrocytes within the lesions. The inflammatory infiltrates in active lesions were characterized by extensive macrophage infiltration associated with large numbers of perivascular granulocytes and eosinophils and rare CD3+ and CD8+ T cells. There was a pronounced perivascular deposition of immunoglobulins (mainly IgM) and complement C9neo antigen in active lesions associated with prominent vascular fibrosis and hyalinization in both active and inactive lesions. The extent of complement activation, eosinophilic infiltration and vascular fibrosis observed in the Devic NMO cases is more prominent compared with that in prototypic multiple sclerosis, and supports a role for humoral immunity in the pathogenesis of NMO. Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation.
Keywords: Devic’s syndrome; eosinophils; humoral immunity; neuromyelitis optica; neuropathology
Abbreviations: ADEM = acute disseminated encephalomyelitis; BBB = blood–brain barrier; EAE = experimental allergic encephalomyelitis; EG MBP = eosinophil granule major basic protein; GFAP = glial fibrillary acidic protein; MAG = myelin-associated glycoprotein; MOG = myelin oligodendrocyte glycoprotein; NMO = neuromyelitis optica; ON = optic neuritis
|
Introduction |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
Devic’s disease [neuromyelitis optica (NMO)] is an idiopathic inflammatory demyelinating disease of the CNS characterized by attacks of optic neuritis (ON) and myelitis (Devic, 1894
, 1895; Gault, 1894). Although, historically, NMO has been regarded as a monophasic disease characterized by nearly simultaneous onset of bilateral ON and myelitis, previous studies suggest that this disease may pursue a relapsing–remitting course (Mandler et al., 1993). A recent review of the Mayo Clinic experience with NMO found that approximately two-thirds of patients in a clinic-based large series had a relapsing form of NMO (Wingerchuk et al., 1999). A number of distinctive characteristics of NMO were identified, including the following: normal MRI scan of the head (occasionally abnormal in a small percentage of early cases), longitudinally extensive signal abnormality in the spinal cord during acute attacks, typically extending over three or more vertebral segments; occasional prominent CSF pleocytosis that may be associated with a polymorphonuclear predominance, and generally poor outcome of attacks, some of which lead to respiratory failure and ventilator dependence, a complication virtually unknown in multiple sclerosis. Unfortunately, no long-term effective treatment has been established for this disease.
The basic histopathological features of NMO have been described previously (Cloys and Netsky, 1970; Mandler et al., 1993; Prineas, 1997): acute spinal cord lesions demonstrate diffuse swelling and softening extending over multiple spinal segments, and occasionally may involve the entire spinal cord in a patchy or continuous distribution. These lesions are characterized by extensive macrophage infiltration associated with myelin and axonal loss, and necrosis of both the grey and white matter of the spinal cord. Perivascular inflammation is variable. Chronic lesions are characterized by gliosis, cystic degeneration, cavitation and atrophy of the spinal cord and optic nerves. An apparent increase in the number and prominence of blood vessels with thickened and hyalinized walls have been described in necrotic and peri-necrotic spinal cord areas (Mandler et al., 1993).
The immunopathological mechanisms responsible for the necrotizing and demyelinating spinal cord and optic nerve lesions in NMO are unknown. Furthermore, whether NMO is a subtype of multiple sclerosis or a distinct disease entity remains controversial. Clinical and serological clues suggest the possibility of B cell dysregulation. We investigated the possible role of humoral mechanisms in producing the necrotizing demyelination of the spinal cord and optic nerves in autopsy material of nine previously well-characterized NMO patients. Lesions were analysed on the basis of myelin protein loss, the geography and extension of plaques, the patterns of axonal and oligodendrocyte destruction, the nature of vascular alterations, the character and distribution of the inflammatory infiltrate, and the immunopathological evidence of complement activation.
|
Material and methods |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
Clinical history of NMO patients
This study was performed on archival material of nine previously well-characterized autopsy cases of NMO (Mandler et al., 1993
, 1998). Material was collected in the Department of Neuropathology at the Mayo Clinic (n = 5) and the Department of Neuropathology at the University of New Mexico (n = 4). Detailed clinical histories were available on all nine cases (eight females; one male; average age 50 years, range 16–80 years). The clinical course was relapsing in eight patients and monophasic in a single case. Mean disease duration (± standard error of the mean) was 2.4 ± 0.8 years. All patients died from respiratory compromise. The presenting syndrome was ON in four patients and myelopathy in five patients, with a mean interval between optic neuropathy and myelopathy of 19 months (range 4–41 months). Three patients had a history of one or more associated autoimmune disorders: hypothyroidism (two), pernicious anaemia (one), thrombocytopenic purpura (one).
Neuropathological controls
Neuropathological controls included other inflammatory demyelinating CNS disorders such as acute disseminated encephalomyelitis (ADEM; n = 3 autopsy cases), pathologically defined as demyelination limited to perivenular areas (Hart and Earle, 1975); and 73 previously well-characterized biopsy (n = 51) and autopsy (n = 22) cases of active multiple sclerosis (Lucchinetti et al., 2000). These controls were included to determine whether the pathological observations found in NMO were unique to this disorder, or rather features representative of the family of related idiopathic inflammatory demyelinating disorders. In addition, three cases of acute spinal cord infarction were included in order to determine whether complement was non-specifically activated in other necrotic inflammatory disorders restricted to the spinal cord.
Neuropathological techniques and immunocytochemistry
All cases underwent assessment of one to six blocks per biopsy case, and up to 20 blocks per autopsy case. All tissue blocks were classified with regard to lesional activity (Brück et al., 1995). Paraffin-embedded 5-µm sections were stained with haematoxylin–eosin, Luxol fast blue (LFB) myelin stain, periodic acid–Schiff (PAS) reaction, and Bielschowsky’s silver impregnation axonal stain.
Immunocytochemistry was performed without modification on paraffin sections using an avidin–biotin or an alkaline phosphatase/anti-alkaline phosphatase technique as previously described in detail (Vass et al., 1990) with the antibodies listed in Table 1. The primary antibodies were omitted in controls. Sections were further analysed for the presence of intact and/or degranulated eosinophils by an indirect immunofluorescence method using specific eosinophil granule major basic protein (EG MBP) antibody as reported previously (Filley et al., 1982).
|
In situ hybridization was performed using digoxigenin-labelled riboprobes specific for proteolipid protein (PLP). The source and specificity of the probes, the labelling techniques and the methods of in situ hybridization have been described in detail previously (Breitschopf et al., 1992
). Following in situ hybridization, the sections were either counterstained with haematoxylin or processed for immunocytochemistry with anti-PLP antibodies as described above. To visualize degenerating cells in tissue sections, DNA fragmentation within cell nuclei was determined using the method of in situ tailing (Gold et al., 1994). The sections were then processed for immunocytochemistry with antibodies against myelin oligo dendrocyte glycoprotein (MOG), glial fibrillary acidic protein (GFAP), T cells and macrophages as described above. Apoptotic oligodendrocytes were defined by nuclear condensation and fragmentation in cells stained by either MOG or 2',3'-cyclic nucleotide phosphodiesterase (CNPase) antibodies.
Lesional staging
Eighty-two lesions were examined from nine autopsy cases of clinically confirmed NMO. Lesions were classified with respect to demyelinating activity, as described previously (Brück et al., 1995). Early active demyelinating lesions were diffusely infiltrated by macrophages immunoreactive for all myelin proteins including MOG (Fig. 1C and D). Late active demyelinating lesions were more advanced with respect to myelin degradation, and were immunoreactive for the major myelin proteins major basic protein (MBP) and PLP, but not for MOG. Remyelinating lesions were characterized by uniformly thin and irregularly arranged myelin sheaths. Inactive demyelinated lesions were completely demyelinated without signs of active demyelination. Demyelinating activity in the NMO lesions was immunocytochemically classified as early active in 21 lesions, late active in 18 lesions, inactive in 35 lesions and remyelinating in eight lesions.
|
Quantitative morphometry of labelled cells
The number of cells stained by immunocytochemistry or in situ hybridization per square unit of tissue was determined on serial sections. A topographical map was established for each lesion outlining the periplaque white matter, zone of active myelin destruction, inactive plaque centre and region of remyelination. The number of cells was determined in each of these distinct plaque areas in 10 standardized microscopic fields of 25 000 µm2, each defined by an ocular morphometric grid. Values in tables and figures represent number of cells per square millimetre.
Statistical analysis
Non-parametric group tests were used to compare groups. All values are expressed as means ± standard error of the mean.
|
Results |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
The basic structural pathology was identical in all nine NMO cases. Extensive demyelination was present across multiple spinal cord levels, associated with cavitation, necrosis and acute axonal pathology (spheroids), in both grey and white matter (Figs 1A and 2C). Lesions were typically located within the central portions of the spinal cord, with peripheral rims of myelin preservation. There was a pronounced loss of oligodendrocytes within all the lesions (Fig. 2D), with rare evidence of Schwann cell remyelination (four lesions). No oligodendrocyte apoptosis was found, and comparative immunocytochemistry of active lesions revealed no selective loss of myelin-associated glycoprotein (MAG; a marker of oligodendrocyte dystrophy). Optic nerves and/or chiasm demonstrated inactive demyelination or partial remyelination in all subjects, with no evidence of ongoing demyelinating activity.
|
The inflammatory infiltrates in actively demyelinating NMO spinal cord lesions were characterized by extensive macrophage/microglial infiltration (Fig. 1B), numerous B lymphocytes, and few CD3+ and CD8+ T-lymphocytes (Fig. 2A and B). This was associated with a prominent eosinophilic and granulocyte perivascular infiltrate in early active demyelinating NMO lesions (Fig. 3A and B). The numbers of eosinophils ranged from 172 to 215/mm2, and granulocytes ranged from 64 to 688/mm2. Immunofluorescence staining for antibody to EG MBP confirmed the presence of both intact and degranulated eosinophils in both early active lesion areas and within the meninges (Fig. 3C–F).
|
Scattered CCR3 immunoreactivity was present on small round cells resembling T lymphocytes in all NMO early active lesions containing perivascular eosinophils, as well as in two early active eosinophil rich Marburg cases of acute multiple sclerosis. Immunoreactivity for the chemokine receptors CXCR3 and CCR5 observed in the NMO cases was similar to those in multiple sclerosis lesions (Sorensen et al., 1999
), with CXCR3 immunoreactivity on predominantly perivascular leukocytes and abundant CCR5 staining on mononuclear phagocytes and lymphocytes in areas of ongoing and completed demyelination. All early active NMO lesions demonstrated a pronounced perivascular Ig and C9neo reactivity in two distinct patterns (Fig. 4A). Total immunoglobulin (Ig) was deposited in a characteristic perivascular rosette pattern, and along the outer rim of thickened vessel walls (Fig. 4B and C). When Ig isotypes were analysed, immunoreactivity was most pronounced for IgM. The Ig reactivity co-localized with a similar pattern of C9neo staining (a marker of complement-mediated tissue injury) in both a rosette and rim perivascular pattern (Fig. 4D and E). Other complement components such as C1q, C3, C4, C6, C7, C8 and C9 were also accentuated in a similar perivascular pattern, but were also present in a relatively diffuse manner. This observation suggests that besides complement activation, diffuse leakage of complement proteins most likely occurred across an impaired blood–brain barrier (BBB). Only C9neo was restricted to sites where complement was activated. A similar rosette and rim pattern of perivascular macrophage staining was also observed (Fig. 4F and G). In addition, there was evidence of vascular fibrosis and hyalinization together with an apparent increase in the density of blood vessels in active spinal cord NMO lesions. There was, however, no evidence of fibrinoid necrosis or granulocyte infiltration of the vessel wall, as seen in acute lesions of necrotizing vasculitis (Fig. 5A and B).
|
|
Table 2 summarizes the neuropathological findings in NMO cases compared with control cases of active multiple sclerosis, ADEM and acute spinal cord infarction. T cells and macrophages were present to a variable degree in all active multiple sclerosis, ADEM and acute spinal cord infarct lesions. Fifty-two per cent of active multiple sclerosis cases (38 of 73) also demonstrated the deposition of immunoglobulin and activated complement (C9neo reactivity). However, Ig and complement deposition in multiple sclerosis was distributed in a pattern quite distinct from the striking perivascular rosette and rim pattern of Ig deposition co-localizing with complement activation observed in NMO cases. In active multiple sclerosis lesions, the degree of complement activation was less pronounced, and was present on degenerating myelin sheaths, within macrophages and on oligodendrocytes along the active plaque edge (Lucchinetti et al., 2000
), as opposed to the perivascular pattern described in NMO lesions. No complement activation or immunoglobulin reactivity was observed in acute spinal cord infarction or ADEM cases. Eosinophils and granulocytes were observed in rare cases of fulminant Marburg acute multiple sclerosis (4% of cases; three of 73), compared with 56% of NMO cases (five of nine cases). Furthermore, all early active NMO lesions (21 of 21) contained eosinophils. No eosinophils were present in ADEM or acute spinal cord infarction cases. Hyalinized vessels were present in all nine NMO cases, but absent from active multiple sclerosis, ADEM and acute spinal cord infarction cases.
|
|
Discussion |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
Unique pathological features of NMO
The pattern of tissue inflammation included extensive complement activation, eosinophil/neutrophil infiltration and vascular fibrosis in early active demyelinating NMO autopsy lesions. These attributes were more prominent and in a unique perivascular pattern compared with typical multiple sclerosis, and supported a role for humoral autoimmunity in the pathogenesis of NMO. We found a uniform pathological pattern in all nine cases of NMO. The co-localization of Ig, C9neo antigen and activated macrophages in the perivascular region, coupled with the prominent vascular hyalinization observed in active NMO lesions, suggests that the CNS vasculature may be an early and specific target of the disease process. These findings also emphasize an important role for complement activation along the classical pathway (Morgan, 1995
). Activation of the classical complement cascade is initiated by the binding of complement component C1q to its receptor in the Fc portion of the antibody molecule. This interaction initiates the classical complement pathway cascade with resultant production of chemo-attractants for macrophages and the eventual production of the membrane attack complex, which inserts itself into cell membranes eventually causing lysis and cell death. Receptor-mediated docking of macrophages to the Fc portion of bound IgG leads to their activation, and to the release of cytokines and oxygen radicals, all of which may contribute to tissue injury. The presence of C9neo in NMO lesions clearly demonstrates that the terminal lytic complement complex (i.e. membrane attack complex) is activated preferentially at perivascular sites. Interestingly, we found that precipitated Ig staining in NMO lesions was most prominent for IgM, which is especially effective in fixing complement (Heyman, 2000). Furthermore, macrophages cannot dock to bound IgM via Fc receptors. Therefore, in NMO, complement must initiate the destruction of myelin, which is then secondarily taken up by macrophages, possibly in complexes with IgM and complement components. Taken together, our observations argue for a primary role of complement activation in mediating tissue injury in NMO.
Relevant experimental animal models
Pathological comparisons between the lesions of one select variant of MOG-induced experimental allergic encephalomyelitis (EAE) and NMO reveal striking similarities (Storch et al., 1998b). The balance of cellular and humoral factors in this model greatly impacts the topography and immunopathology of the lesions. Interestingly, those genetic strains or immunization protocols that favour humoral immune mechanisms reproduce the pathological hallmarks of NMO in the animal. Brown Norway rats sensitized with soluble MOG in incomplete Freund’s adjuvant mount a very prominent antibody response, and develop a chronic disease with pronounced demyelination, most frequently in the spinal cord and optic nerve. Active demyelination in these experimental lesions is associated with the deposition of immunoglobulin and complement activation, and the acute inflammatory infiltrates contain neutrophilic and eosinophilic granulocytes. The parallels in lesional topography, complement activation and eosinophilic inflammation observed between NMO and those specific models of MOG-induced EAE that drive a humoral response further supports a role for humoral immunity in the pathogenesis of NMO.
Proposed pathogenic mechanism in NMO
Based on these novel immunopathological observations, we speculate on several mechanisms that may be involved in NMO pathogenesis. The pronounced Ig reactivity co-localizing with complement activation at sites of vessel damage suggest the perivascular space may be the primary site of injury in NMO. This may be due to a specific antibody targeted to a vascular antigen. Alternatively, antigen liberated within the CNS in the course of the destructive process may reach the perivascular space and be recognized there by antibodies derived from the circulation. Finally, a non-specific inflammatory reaction initiated by the deposition of circulating immune complexes may be involved. In either scenario, the classical complement pathway is activated, and leads to the recruitment of activated macrophages to these perivascular sites where they bind either via a receptor for complement components or Ig/Fc receptor. Activated macrophages, together with eosinophils and neutrophils, locally generate cytokines, proteases and oxygen/nitrogen free radicals, which may contribute to both vascular and parenchymal damage, resulting in non-selective bystander destruction of both grey and white matter, including axons and oligodendrocytes. Increased vascular permeability and oedema may contribute to parenchymal damage via secondary ischaemia, and might account for the typical central location of NMO plaques within the spinal cord (Prineas and McDonald, 1997). A similar central location is found in severe cases of MOG-EAE, and this phenomenon is most likely due to oedema-induced ischaemia (Lassmann, 1983). Novel antigens liberated during the destructive process may further amplify the destructive immune response in NMO.
Complement may be activated non-specifically in response to tissue necrosis. Given the necrotic nature of NMO lesions, we considered that complement activation might be a secondary phenomenon occurring as a result, rather than as a cause, of necrosis. This possibility seems unlikely given the fact that we did not observe complement activation in the acute spinal cord infarction cases. In addition, C9neo antigen deposition was not observed in acute or chronic white matter brain infarcts (H. Rauschka, B. Kornek, C. Stadelmann, A. Steffenl, W. Brück, C. Lucchinetti et al., unpublished results).
Role of eosinophils in NMO
One of the most striking novel features we describe regarding the histopathology of active NMO lesions is the intense perivascular and meningeal infiltration of the spinal cord with eosinophils and neutrophils. Activated eosinophils release basic granule proteins such as MBP, eosinophil-derived neurotoxin, eosinophil cationic protein and eosinophil peroxidase (Kaneko et al., 1997). These granules have cytotoxic properties and serve as markers for eosinophil activation (Venge, 1995). In addition to elevated numbers of eosinophils within the NMO lesions, we have confirmed the presence of eosinophil degranulation in spinal cord tissue of NMO patients. We have also demonstrated evidence for CCR3 expression in NMO lesions. CCR3 has been shown to be the principal receptor for the chemokine eotaxin, a potent eosinophil chemo-attractant. CCR3 is expressed primarily by eosinophils in humans (Ponath et al., 1996). Eotaxin signalling through CCR3 is an important mediator of eosinophil recruitment (Daugherty et al., 1996). CCR3 is selectively expressed by human T helper 2 (Th2) cells and therefore is associated with Th2 responses (Sallusto et al., 1998). Taken together, our data provide morphological evidence that eosinophils are increased in number, functionally active and likely contribute to the destructive inflammatory process in NMO.
The cytotoxicity of eosinophil granule proteins has been well established (Corrigan and Kay, 1996). Eosinophils are the dominant source of interleukin-4, which may cause a Th1 to Th2 shift in cytokine profile (Rumbley et al., 1999). Eosinophils are thought to play a major role in a variety of human diseases, including allergic inflammation, asthma, malignancy and host defense against helminth infections (Rothenberg et al., 1996). Eosinophil granule MBP is highly toxic to endothelial cells in a dose-dependent manner and is thought to contribute to vessel damage in necrotizing vasculitis associated with eosinophil infiltration (Chen et al., 1996). There is a single report of CSF eosinophilia in a child presenting with recurrent transverse myelitis (Snead and Kalavsky, 1976), as well as a report of eosinophilic vasculitis, pericarditis and hypocomplementaemia in a patient presenting with a disorder resembling NMO (Tanphaichitr, 1980). More recently, a retrospective study on multiple sclerosis in Aboriginals revealed an increased frequency in optic nerve and spinal cord involvement compared with non-Aboriginals (Mirsattari et al., 2001). They described a single autopsy case characterized by necrosis and eosinophil infiltrates within the spinal cord lesion that they attributed to chronic ß-interferon treatment. However, none of the NMO patients included in our series received ß-interferon therapy, and therefore this does not sufficiently explain the presence of eosinophils in NMO lesions.
The exact role of eosinophils in NMO immunopathology is unclear. It remains to be determined whether eosinophil activation is a primary or secondary event in NMO lesion formation. Activation of complement generates several biologically active peptides that have potent chemo-attractant potential (Asghar, 1998). The most clinically relevant complement-derived chemotactic factor is C5a, a cleavage product of the fifth component of complement. In addition to its chemotactic activity, C5a is a potent factor for activating eosinophils, including the release of eosinophil granule proteins (Kernen et al., 1991). Complement activation within the lesions may have induced the production of eosinophil chemotactic factors, resulting in the secondary activation of eosinophils and the subsequent release of eosinophil granule proteins in vessel walls.
Possible explanations for the restricted topography of NMO lesions
The reasons why the spinal cord and optic nerve are preferentially affected in NMO are unknown. There are several possible explanations. It is possible, although unlikely, that these sites harbour a restricted CNS or vascular antigen. Alternatively, it may be that the spinal cord and optic nerve are particularly vulnerable to antibody-mediated injury due to the inherent weakness of the BBB at these sites. The normal BBB is highly impermeable to plasma proteins and circulating leukocytes, and thus it can protect the CNS against an immunological reaction. However, in those areas lacking an effective BBB, such as the spinal nerve roots, it may be proposed that circulating pathogenic antibodies could gain access to the CNS via these structures and diffuse out into the immediate vicinity. In EAE models, active lesions predominantly affect the spinal cord (Lassmann, 1983). ON in EAE also tends to predictably occur in the retrobulbar optic nerve (Guy and Rao, 1984). Lesions at these two sites are thought to reflect the higher degree of BBB permeability in these regions compared with the brain (Rao, 1981; Guy and Rao, 1984; Butter et al., 1991). The increased BBB permeability in the spinal cord may also be due to the inherent vascular properties of this region, where capillaries are larger than those in the brain. Thus, on a background of an inflammatory process in the presence of extremely high antibody titres, lesions might preferentially, but not exclusively, affect the spinal cord and optic nerve. This hypothesis would be compatible with the observation that in late stages of NMO, lesions often disseminate into other CNS regions (Wingerchuk et al., 1999).
Clinical associations with NMO
Several clinical associations with NMO suggest this disorder is distinct from multiple sclerosis. NMO patients often have circulating auto-antibodies at frequencies that exceed those seen in classical multiple sclerosis (Wingerchuk et al., 1999). The pathogenicity of these auto-antibodies is unknown: they might cause damage directly through the recognition of epitopes on normal cells, or indirectly through the formation of immune complexes that deposit in normal tissue and activate the complement cascade. Their presence in Devic patients may also reflect a more widespread B cell response. Prominent antibody responses can also be found with respect to endogenous myelin antigens, such as MOG. A recent study analysed antibody responses to MOG, MBP and S100ß in the serum of four cases of Devic’s disease (Haase and Schmidt, 2001). The authors reported a prominent anti-MOG response in all patients, MBP antibodies in two and S100ß antibodies in one patient, and, similar to our data, concluded their findings were consistent with a widespread B cell immune response in Devic patients.
In contrast to classical multiple sclerosis, there are numerous reports of inflammatory opticospinal disease associated with connective tissue as well as other autoimmune disorders (April et al., 1976; Kinney et al., 1979; Goldman et al., 1984; Nambu et al., 1988; Lindsey et al., 1992; Simeon-Aznar et al., 1992; Bonnet et al., 1999; Mochizuki et al., 2000). Unlike multiple sclerosis, there is a racial predilection for NMO in non-whites (O’Riordan et al., 1996). Japanese patients with ‘opticospinal’ multiple sclerosis behave similar to relapsing NMO patients, and differ immunogenetically from Japanese with Western multiple sclerosis, consistently being HLA-DR2 negative (Shibasaki et al., 1981). Furthermore, plasma exchange has been reported to be effective for the management of acute relapses in NMO patients with or without associated connective tissue disorders (Konttinen et al, 1987; Fletchner and Baum, 1994; Weinshenker et al., 1999; Biliciler et al., 2001). Plasma exchange is known to reduce the amount of circulating auto-antibodies and immune complexes (Clark et al., 1991), which might explain its effectiveness in some NMO patients.
Conclusions
This study suggests four separate lines of evidence supporting a role for humoral mechanisms in the pathogenesis of NMO: the lesion pathology, similarities with a select variant of MOG-induced EAE, clinical association with antibody-mediated collagen vascular disorders and the response to plasma exchange. Although complement activation is observed in a subset of classical multiple sclerosis patients (Storch et al., 1998a; Lucchinetti et al., 2000), the pattern and pronounced perivascular distribution of complement activation seen in NMO is unique. Despite differences in the clinical manifestations, imaging findings, CSF biochemistries and pathology between NMO and multiple sclerosis, the distinction between these disorders remains controversial (Mandler et al., 1993; Wingerchuk et al., 1999). Reduced levels of the neuro-inflammatory metalloproteinase marker MMP-9 in the CSF of patients with NMO supports the possibility of a different pathogenic mechanism of lesion production, since MMP-9 is markedly elevated in acute multiple sclerosis CSF (Mandler et al., 2001). Moreover, tissue inhibitor of metalloproteinases (TIMP-1) was significantly reduced in relapsing–remitting multiple sclerosis CSF, but not in NMO CSF (Mandler et al., 2001). These CSF biochemical differences might well be related to differences in the tissue inflammatory reaction in multiple sclerosis and in Devic’s NMO. However, since the entire spectrum of multiple sclerosis pathology, including optico-spinal disease, can be reproduced in the MOG-induced EAE rat model using the same MOG antigen but different strain/sensitization regimens (Storch et al., 1998b), it is still not clear whether NMO is pathogenetically distinct from multiple sclerosis, or rather reflects the effects of distinct host immunogenetic and environmental factors at play.
NMO is an aggressive and disabling inflammatory demyelinating disease, and treatment for this condition is often ineffective. Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation.
|
Acknowledgements |
|---|
We wish to thank Helene Breitschopf and Patricia Ziemer for their expert technical assistance. This study was funded by the United States National Multiple Sclerosis Society (grant RG 3051-A-1) and a grant from the Bundesministerium für Bildung, Wissenschaft und Kunst, Austria (grant GZ 70.056/2-Pr/4/99).
|
References |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionReferences |
|---|
April RS, Vansonnenberg E. A case of neuromyelitis optica (Devic’s syndrome) in systemic lupus erythematosus: clinicopathologic report and review of the literature. Neurology 1976; 26: 1066–70.
Asghar SS, Pasch MC. Complement as a promiscuous signal transduction device. [Review]. Lab Invest 1998; 78: 1203–25.[Web of Science][Medline]
Biliciler S, Uygucgil H, Saip S, Altintas A, Soysal T, Ozdemir SE, et al. Plasmapheresis in multiple sclerosis patients with different indications [abstract]. Mult Scler 2001; 7 Suppl 1: S64.
Bonnet F, Mercie P, Morlat P, Hocke C, Vergnes C, Ellie E, et al. Devic’s neuromyelitis optica during pregnancy in a patient with systemic lupus erythematosus. Lupus 1999; 8: 244–7.
Breitschopf H, Suchanek G, Gould RM, Colman DR, Lassmann H. In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol (Berl) 1992; 84: 581–7.[Medline]
Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38: 788–96.[Web of Science][Medline]
Butter C, Baker D, O’Neill JK, Turk JL. Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice. J Neurol Sci 1991; 104: 9–12.[Web of Science][Medline]
Chen K, Su WPD, Pittelkow MR, Conn DL, George RT, Leiferman KM. Eosinophilic vasculitis in connective tissue disease. J Am Acad Dermatol 1996; 35: 173–82.[Web of Science][Medline]
Clark WF, Dan PC, Euler HH, Guillevin L, Harsford J, Heer AH, et al. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. J Clin Apheresis 1991; 6: 40–7.[Medline]
Cloys DE, Netsky MG. Neuromyelitis optica. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology, Vol. 9. Amsterdam: North-Holland; 1970. p. 426–36.
Corrigan CJ, Kay AB. T-cell/eosinophil interactions in the induction of asthma. [Review]. Eur Respir J 1996; Suppl 22: 72s–8s.
Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz I, Sirotina A, Springer MS. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996; 183: 2349–54.
Devic E. Myelitis subaigue compliquess de neurite optique. Bull Med 1894; 8: 1033–1034.
Devic E. Myelite aigue dorse-lombaire de neurite optique, autopsie. Congress Francais Medicine (Premiere Session, Lyon). 1895; 1: 434–9.
Filley WV, Holley KE, Kephart GM, Gleich GJ. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982; 2: 11–6.[Web of Science][Medline]
Fletchner KM, Baum K. Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis. J Neurol Sci 1994; 126: 146–8.[Web of Science][Medline]
Gault F. De la neuromyelite optique aigue [thesis]. Lyon; 1894.
Gold R, Schmied M, Giegrich G, Breitschopf H, Hartung HP, Toyka KV, et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994; 71: 219–25.[Web of Science][Medline]
Goldman M, Herode A, Borenstein S, Zanen A. Optic neuritis, transverse myelitis, and anti-DNA antibodies nine years after thymectomy for myasthenia gravis. Arthritis Rheum 1984; 27: 701–3.[Web of Science][Medline]
Guy J, Rao NA. Acute and chronic experimental optic neuritis. Alteration in the blood–optic nerve barrier. Arch Ophthalmol 1984; 102: 450–4.
Haase CG, Schmidt S. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic’s neuromyelitis optica. Neurosci Lett 2001; 307: 131–3.[Web of Science][Medline]
Hart MN, Earle KM. Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975; 38: 585–91.
Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. [Review]. Annu Rev Immunol 2000; 18: 709–37.[Web of Science][Medline]
Kaneko M, Kita H, Gleich GJ. Eosinophil basic proteins. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, editors. Asthma. Philadelphia: Lippincott-Raven; 1997. p. 593–607.
Kernen P, Wymann MP, von Tscharner V, Deranleau DA, Tai PC, Spry CJ, et al. Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils. J Clin Invest 1991; 87: 2012–7.
Kinney EL, Berdoff RL, Rao NS, Fox LM. Devic’s syndrome and systemic lupus erythematosus: a case report with necropsy. Arch Neurol 1979; 36: 643–4.
Konttinen YT, Kinnunen E, von Bonsdorff M, Lillqvist P, Immonen I, Bergroth V, et al. Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjogren’s syndrome. Arthritis Rheum 1987; 30: 339–44.[Web of Science][Medline]
Lassmann H. Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. Schriftenr Neurol 1983; 25: 1–135.
Lindsey JW, Albers GW, Steinman L. Recurrent transverse myelitis, myasthenia gravis, and autoantibodies. Ann Neurol 1992; 32: 407–9.[Web of Science][Medline]
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707–17.[Web of Science][Medline]
Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993; 34: 162–8.[Web of Science][Medline]
Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219–20.
Mandler RN, Dencoff JD, Midani F, Ford CC, Ahmed W, Rosenberg GA. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic’s neuromyelitis optica. Brain 2001; 124: 493–8.
Mirsattari SM, Johnston JB, McKenna R, Del Bigio MR, Orr P, Ross RT, et al. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology 2001; 56: 317–23.
Mochizuki A, Hayashi A, Hisahara S, Shoji S. Steroid-responsive Devic’s variant in Sjogren’s syndrome. Neurology 2000; 54: 1391–2.
Morgan BP. Physiology and pathophysiology of complement progress and trends. [Review]. Crit Rev Clin Lab Sci 1995; 32: 265–98.[Web of Science][Medline]
Nambu M, Hayakawa Y, Ito T, Takeda Z, Sakamoto Y, Mikawa H. Hypergammaglobulinemic purpura associated with multiple sclerosis. J Pediatr 1988; 113: 331–3.[Web of Science][Medline]
O’Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60: 382–7.
Ponath PD, Qin S, Post TW, Wang J, Wu L, Gerard NP, et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996; 183: 2437–48.
Prineas JW, McDonald WI. Demyelinating diseases. In: Graham DI, Lantos PL, editors. Greenfield’s neuropathology. 6th ed. London: Arnold; 1997. p. 813–96.
Rao NA. Chronic experimental allergic optic neuritis. Invest Ophthalmol Vis Sci 1981; 20: 159–72.
Rothenberg M, Ownbey PD, Mehlhop PD, Loiselle PM, van de Rijn M, Bonventre JV, et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med 1996; 2: 334–48.[Web of Science][Medline]
Rumbley CA, Sugaya H, Zekavat SA, El Refaei M, Perrin PJ, Phillips SM. Activated eosinophils are the major source of Th2-associated cytokines in the schistosome granuloma. J Immunol 1999; 162: 1003–9.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187: 875–83.
Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci 1981; 49: 253–71.[Web of Science][Medline]
Simeon-Aznar CP, Tolosa-Vilella C, Cuenca-Luque R, Jordana-Comajuncosa R, Ordi-Ros J, Bosch-Gil JA. Transverse myelitis in systemic lupus erythematosus: two cases with magnetic resonance imaging. Br J Rheumatol 1992; 31: 555–8.
Snead OC 3rd, Kalavsky SM. Cerebrospinal fluid eosinophilia: a manifestation of a disorder resembling multiple sclerosis in childhood. J Pediatr 1976; 89: 83–4.[Web of Science][Medline]
Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807–15.[Web of Science][Medline]
Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998a; 43: 465–71.[Web of Science][Medline]
Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998b; 8: 681–94.[Web of Science][Medline]
Tanphaichitr K. Multiple sclerosis associated with eosinophilic vasculitis, pericarditis, and hypocomplementemia. Arch Neurol 1980; 37: 314–415.
Vass K, Lassmann H. Intrathecal application of interferon gamma: progressive appearance of MHC antigens within the rat nervous system. Am J Pathol 1990; 137: 789–800.[Abstract]
Venge P. Monitoring of asthma inflammation by serum measurements of eosinophil cationic protein (ECP): a new clinical approach to asthma management. Resp Med 1995; 89: 1–2.[Web of Science][Medline]
Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878–86.[Web of Science][Medline]
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53: 1107–14.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T Matsushita, N Isobe, T Matsuoka, N Shi, Y Kawano, X. Wu, T Yoshiura, Y Nakao, T Ishizu, and J. Kira Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese Multiple Sclerosis, July 1, 2009; 15(7): 834 - 847. [Abstract] [PDF]
|
|
|
|
 |
|
 S Viegas, A Weir, M Esiri, W Kuker, P Waters, M I Leite, A Vincent, and J Palace Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 679 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Nakamura, T Misu, K Fujihara, I Miyazawa, I Nakashima, T Takahashi, S Watanabe, and Y Itoyama Occurrence of acute large and edematous callosal lesions in neuromyelitis optica Multiple Sclerosis, June 1, 2009; 15(6): 695 - 700. [Abstract] [PDF]
|
|
|
|
|
|
D. Bichuetti, E. Oliveira, N. Souza, R. Rivero, and A. Gabbai Neuromyelitis optica in Brazil: a study on clinical and prognostic factors Multiple Sclerosis, May 1, 2009; 15(5): 613 - 619. [Abstract] [PDF]
|
|
|
|
|
|
H Zephir, I Fajardy, O Outteryck, F Blanc, N Roger, M Fleury, G Rudolf, R Marignier, S Vukusic, C Confavreux, et al. Is neuromyelitis optica associated with human leukocyte antigen? Multiple Sclerosis, May 1, 2009; 15(5): 571 - 579. [Abstract] [PDF]
|
|
|
|
|
|
M Bonnan, R Valentino, S Olindo, H Mehdaoui, D Smadja, and P Cabre Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder Multiple Sclerosis, April 1, 2009; 15(4): 487 - 492. [Abstract] [PDF]
|
|
|
|
 |
|
 R. T. Naismith, N. T. Tutlam, J. Xu, E. C. Klawiter, J. Shepherd, K. Trinkaus, S. K. Song, and A. H. Cross Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis Neurology, March 24, 2009; 72(12): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Doi, T Matsushita, N Isobe, T Matsuoka, M Minohara, H Ochi, and J. Kira Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody Multiple Sclerosis, March 1, 2009; 15(3): 304 - 310. [Abstract] [PDF]
|
|
|
|
|
|
S. M. Magana, M. Matiello, S. J. Pittock, A. McKeon, V. A. Lennon, A. A. Rabinstein, E. Shuster, O. H. Kantarci, C. F. Lucchinetti, and B. G. Weinshenker Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders Neurology, February 24, 2009; 72(8): 712 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jarius, F. Aboul-Enein, P. Waters, B. Kuenz, A. Hauser, T. Berger, W. Lang, M. Reindl, A. Vincent, and W. Kristoferitsch Antibody to aquaporin-4 in the long-term course of neuromyelitis optica Brain, November 1, 2008; 131(11): 3072 - 3080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Hinson, S. F. Roemer, C. F. Lucchinetti, J. P. Fryer, T. J. Kryzer, J. L. Chamberlain, C. L. Howe, S. J. Pittock, and V. A. Lennon Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2 J. Exp. Med., October 27, 2008; 205(11): 2473 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Vincent, P. Saikali, R. Cayrol, A. D. Roth, A. Bar-Or, A. Prat, and J. P. Antel Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment J. Immunol., October 15, 2008; 181(8): 5730 - 5737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Novak, A. E. Lovett-Racke, and M. K. Racke Monoclonal Antibody Therapies and Neurologic Disorders Arch Neurol, September 1, 2008; 65(9): 1162 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Waters, S. Jarius, E. Littleton, M. I. Leite, S. Jacob, B. Gray, R. Geraldes, T. Vale, A. Jacob, J. Palace, et al. Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis Arch Neurol, July 1, 2008; 65(7): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. de Seze, F. Blanc, L. Jeanjean, H. Zephir, P. Labauge, M. Bouyon, L. Ballonzoli, G. Castelnovo, M. Fleury, S. Defoort, et al. Optical Coherence Tomography in Neuromyelitis Optica Arch Neurol, July 1, 2008; 65(7): 920 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Moreh, I Gartsman, D Karussis, D Rund, N Hiller, and Z Meiner Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment Multiple Sclerosis, July 1, 2008; 14(6): 860 - 861. [PDF]
|
|
|
|
|
|
M. Krumbholz, H. Faber, F. Steinmeyer, L.-A. Hoffmann, T. Kumpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, et al. Interferon-{beta} increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity Brain, June 1, 2008; 131(6): 1455 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Marignier, J. De Seze, S. Vukusic, F. Durand-Dubief, H. Zephir, P. Vermersch, P. Cabre, G. Cavillon, J. Honnorat, and C. Confavreux NMO-IgG and Devic's neuromyelitis optica: a French experience Multiple Sclerosis, May 1, 2008; 14(4): 440 - 445. [Abstract] [PDF]
|
|
|
|
|
|
T. Carlson, M. Kroenke, P. Rao, T. E. Lane, and B. Segal The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease J. Exp. Med., April 14, 2008; 205(4): 811 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsushita, T. Matsuoka, T. Ishizu, H. Kikuchi, M. Osoegawa, Y. Kawano, F. Mihara, Y. Ohyagi, and J.-i. Kira Anterior periventricular linear lesions in optic-spinal multiple sclerosis: a combined neuroimaging and neuropathological study Multiple Sclerosis, April 1, 2008; 14(3): 343 - 353. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Dinkin, D. M. Cestari, M. C. Stein, S. D. Brass, and S. Lessell NMO Antibody-Positive Recurrent Optic Neuritis Without Clear Evidence of Transverse Myelitis Arch Ophthalmol, April 1, 2008; 126(4): 566 - 570. [Full Text] [PDF]
|
|
|
|
|
|
R. A Wilcox, J. Burrow, M. Slee, J. Craig, and D. Thyagarajan Neuromyelitis optica (Devic's disease) in a patient with syphilis Multiple Sclerosis, March 1, 2008; 14(2): 268 - 271. [Abstract] [PDF]
|
|
|
|
|
|
M. Levy, J. Birnbaum, and D. Kerr Finding NMO: Neuromyelitis optica in children Neurology, January 29, 2008; 70(5): 334 - 335. [Full Text] [PDF]
|
|
|
|
|
|
B. Banwell, S. Tenembaum, V. A. Lennon, E. Ursell, J. Kennedy, A. Bar-Or, B. G. Weinshenker, C. F. Lucchinetti, and S. J. Pittock Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders Neurology, January 29, 2008; 70(5): 344 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Pittock, V. A. Lennon, J. de Seze, P. Vermersch, H. A. Homburger, D. M. Wingerchuk, C. F. Lucchinetti, H. Zephir, K. Moder, and B. G. Weinshenker Neuromyelitis Optica and Non Organ-Specific Autoimmunity Arch Neurol, January 1, 2008; 65(1): 78 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Blanc, H. Zephir, C. Lebrun, P. Labauge, G. Castelnovo, M. Fleury, F. Sellal, C. Tranchant, K. Dujardin, P. Vermersch, et al. Cognitive Functions in Neuromyelitis Optica Arch Neurol, January 1, 2008; 65(1): 84 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Papais-Alvarenga, S. C. Carellos, M. P. Alvarenga, C. Holander, R. P. Bichara, and L. C. S. Thuler Clinical Course of Optic Neuritis in Patients With Relapsing Neuromyelitis Optica Arch Ophthalmol, January 1, 2008; 126(1): 12 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Hinson, S. J. Pittock, C. F. Lucchinetti, S. F. Roemer, J. P. Fryer, T. J. Kryzer, and V. A. Lennon Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica Neurology, December 11, 2007; 69(24): 2221 - 2231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Marik, P. A. Felts, J. Bauer, H. Lassmann, and K. J. Smith Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain, November 1, 2007; 130(11): 2800 - 2815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Yuksel, N. Senbil, D. Yilmaz, and Y.K. Yavuz Gurer Devic's Neuromyelitis Optica in an Infant Case J Child Neurol, September 1, 2007; 22(9): 1143 - 1146. [Abstract] [PDF]
|
|
|
|
|
|
T. Braley and D. D. Mikol Neuromyelitis Optica in a Mother and Daughter Arch Neurol, August 1, 2007; 64(8): 1189 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Yu, C. Z. Zhu, K. C. Li, Y. Xuan, W. Qin, H. Sun, and P. Chan Relapsing Neuromyelitis Optica and Relapsing-Remitting Multiple Sclerosis: Differentiation at Diffusion-Tensor MR Imaging of Corpus Callosum Radiology, July 1, 2007; 244(1): 249 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Weinshenker Neuromyelitis Optica Is Distinct From Multiple Sclerosis Arch Neurol, June 1, 2007; 64(6): 899 - 901. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Galetta and J. Bennett Neuromyelitis Optica Is a Variant of Multiple Sclerosis Arch Neurol, June 1, 2007; 64(6): 901 - 903. [Full Text] [PDF]
|
|
|
|
|
|
G.J.D. Hengstman, P. Wesseling, C.W.G.M. Frenken, and P.J.H. Jongen Neuromyelitis optica with clinical and histopathological involvement of the brain Multiple Sclerosis, June 1, 2007; 13(5): 679 - 682. [Abstract] [PDF]
|
|
|
|
|
|
A. Compston Complexity and heterogeneity in demyelinating disease Brain, May 1, 2007; 130(5): 1178 - 1180. [Full Text] [PDF]
|
|
|
|
|
|
S. F. Roemer, J. E. Parisi, V. A. Lennon, E. E. Benarroch, H. Lassmann, W. Bruck, R. N. Mandler, B. G. Weinshenker, S. J. Pittock, D. M. Wingerchuk, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis Brain, May 1, 2007; 130(5): 1194 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Misu, K. Fujihara, A. Kakita, H. Konno, M. Nakamura, S. Watanabe, T. Takahashi, I. Nakashima, H. Takahashi, and Y. Itoyama Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis Brain, May 1, 2007; 130(5): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsuoka, T. Matsushita, Y. Kawano, M. Osoegawa, H. Ochi, T. Ishizu, M. Minohara, H. Kikuchi, F. Mihara, Y. Ohyagi, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese Brain, May 1, 2007; 130(5): 1206 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takahashi, K. Fujihara, I. Nakashima, T. Misu, I. Miyazawa, M. Nakamura, S. Watanabe, Y. Shiga, C. Kanaoka, J. Fujimori, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre Brain, May 1, 2007; 130(5): 1235 - 1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Ness, D. Chabas, A. D. Sadovnick, D. Pohl, B. Banwell, B. Weinstock-Guttman, and for the International Pediatric MS Study Group Clinical features of children and adolescents with multiple sclerosis Neurology, April 17, 2007; 68(16_suppl_2): S37 - S45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Miyazawa, I. Nakashima, A. Petzold, K. Fujihara, S. Sato, and Y. Itoyama High CSF neurofilament heavy chain levels in neuromyelitis optica Neurology, March 13, 2007; 68(11): 865 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Papeix, J-S Vidal, J de Seze, C Pierrot-Deseilligny, A Tourbah, B Stankoff, C Lebrun, T Moreau, P Vermersch, B Fontaine, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica Multiple Sclerosis, March 1, 2007; 13(2): 256 - 259. [Abstract] [PDF]
|
|
|
|
|
|
S Watanabe, I Nakashima, T Misu, I Miyazawa, Y Shiga, K Fujihara, and Y Itoyama Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica Multiple Sclerosis, January 1, 2007; 13(1): 128 - 132. [Abstract] [PDF]
|
|
|
|
 |
|
 S Love Demyelinating diseases. J. Clin. Pathol., November 1, 2006; 59(11): 1151 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Scott, S. L. Kassab, and S. J. Pittock Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol, October 1, 2006; 63(10): 1398 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Nakashima, K Fujihara, I Miyazawa, T Misu, K Narikawa, M Nakamura, S Watanabe, T Takahashi, S Nishiyama, Y Shiga, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG J. Neurol. Neurosurg. Psychiatry, September 1, 2006; 77(9): 1073 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Giovannoni Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype J. Neurol. Neurosurg. Psychiatry, September 1, 2006; 77(9): 1001 - 1002. [Full Text] [PDF]
|
|
|
|
|
|
D Merkler, B Schmelting, B Czeh, E Fuchs, C Stadelmann, and W Bruck Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions Multiple Sclerosis, August 1, 2006; 12(4): 369 - 374. [Abstract] [PDF]
|
|
|
|
|
|
R. Gold, C. Linington, and H. Lassmann Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research Brain, August 1, 2006; 129(8): 1953 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Lalive, T. Menge, I. Barman, B. A. Cree, and C. P. Genain Identification of new serum autoantibodies in neuromyelitis optica using protein microarrays. Neurology, July 11, 2006; 67(1): 176 - 177. [Full Text] [PDF]
|
|
|
|
|
|
B. Weinstock-Guttman, M. Ramanathan, N. Lincoff, S. Q. Napoli, J. Sharma, J. Feichter, and R. Bakshi Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (devic disease). Arch Neurol, July 1, 2006; 63(7): 957 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Pittock, B. G. Weinshenker, C. F. Lucchinetti, D. M. Wingerchuk, J. R. Corboy, and V. A. Lennon Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol, July 1, 2006; 63(7): 964 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kister, S. Gulati, C. Boz, R. Bergamaschi, G. Piccolo, J. Oger, and M. L. Swerdlow Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol, June 1, 2006; 63(6): 851 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jacob and M. Boggild Neuromyelitis optica Practical Neurology, June 1, 2006; 6(3): 180 - 184. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Wingerchuk, V. A. Lennon, S. J. Pittock, C. F. Lucchinetti, and B. G. Weinshenker Revised diagnostic criteria for neuromyelitis optica Neurology, May 23, 2006; 66(10): 1485 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rubiera, J. Rio, M. Tintore, C. Nos, A. Rovira, N. Tellez, and X. Montalban Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis Neurology, May 23, 2006; 66(10): 1568 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.S. Yu, F.C. Lin, K.C. Li, T.Z. Jiang, C.Z. Zhu, W. Qin, H. Sun, and P. Chan Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 1009 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M H Barnett, A P. Henderson, and J W Prineas The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion Multiple Sclerosis, April 1, 2006; 12(2): 121 - 132. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Pittock, V. A. Lennon, K. Krecke, D. M. Wingerchuk, C. F. Lucchinetti, and B. G. Weinshenker Brain abnormalities in neuromyelitis optica. Arch Neurol, March 1, 2006; 63(3): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Nakamura, M Endo, K Murakami, H Konno, K Fujihara, and Y Itoyama An autopsied case of neuromyelitis optica with a large cavitary cerebral lesion Multiple Sclerosis, December 1, 2005; 11(6): 735 - 738. [Abstract] [PDF]
|
|
|
|
|
|
A. Y Poppe, Y. Lapierre, D. Melancon, D. Lowden, L. Wardell, L. M Fullerton, and A. Bar-Or Neuromyelitis optica with hypothalamic involvement Multiple Sclerosis, October 1, 2005; 11(5): 617 - 621. [Abstract] [PDF]
|
|
|
|
|
|
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Lennon, T. J. Kryzer, S. J. Pittock, A.S. Verkman, and S. R. Hinson IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel J. Exp. Med., August 15, 2005; 202(4): 473 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lolli, B. Mulinacci, A. Carotenuto, B. Bonetti, G. Sabatino, B. Mazzanti, A. M. D'Ursi, E. Novellino, M. Pazzagli, L. Lovato, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis PNAS, July 19, 2005; 102(29): 10273 - 10278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ishizu, M. Osoegawa, F.-J. Mei, H. Kikuchi, M. Tanaka, Y. Takakura, M. Minohara, H. Murai, F. Mihara, T. Taniwaki, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis Brain, May 1, 2005; 128(5): 988 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A.C. Cree, S. Lamb, K. Morgan, A. Chen, E. Waubant, and C. Genain An open label study of the effects of rituximab in neuromyelitis optica Neurology, April 12, 2005; 64(7): 1270 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Correale and M. Fiol Activation of humoral immunity and eosinophils in neuromyelitis optica Neurology, December 28, 2004; 63(12): 2363 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sakuma, K. Kohyama, I.-K. Park, A. Miyakoshi, N. Tanuma, and Y. Matsumoto Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats Brain, October 1, 2004; 127(10): 2201 - 2213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S J Pittock, B G Weinshenker, and E F M Wijdicks Mechanical ventilation and tracheostomy in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1331 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Pradhan and V N Mishra A central demyelinating disease with atypical features Multiple Sclerosis, June 1, 2004; 10(3): 308 - 315. [Abstract] [PDF]
|
|
|
|
|
|
M J Eikelenboom, J Killestein, B M. Uitdehaag, and C H Polman Letter to the Editor Multiple Sclerosis, June 1, 2004; 10(3): 334 - 335. [PDF]
|
|
|
|
 |
|
 M. Kerschensteiner, C. Stadelmann, B. S. Buddeberg, D. Merkler, F. M. Bareyre, D. C. Anthony, C. Linington, W. Bruck, and M. E. Schwab Targeting Experimental Autoimmune Encephalomyelitis Lesions to a Predetermined Axonal Tract System Allows for Refined Behavioral Testing in an Animal Model of Multiple Sclerosis Am. J. Pathol., April 1, 2004; 164(4): 1455 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. -C. Antoine, J. -P. Camdessanche, L. Absi, F. Lassabliere, and L. Feasson Devic disease and thymoma with anti-central nervous system and antithymus antibodies Neurology, March 23, 2004; 62(6): 978 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Bergamaschi, S Tonietti, D Franciotta, E Candeloro, E Tavazzi, G Piccolo, A Romani, and V Cosi Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations Multiple Sclerosis, February 1, 2004; 10(1): 2 - 4. [Abstract] [PDF]
|
|
|
|
|
|
I. Nakashima, K. Fujihara, J. Fujimori, K. Narikawa, T. Misu, and Y. Itoyama Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica Neurology, January 13, 2004; 62(1): 144 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Oleszak, J. R. Chang, H. Friedman, C. D. Katsetos, and C. D. Platsoucas Theiler's Virus Infection: a Model for Multiple Sclerosis Clin. Microbiol. Rev., January 1, 2004; 17(1): 174 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C M Isbister, P J Mackenzie, D Anderson, N K Wade, and J Oger Co-occurrence of multiple sclerosis and myasthenia gravis in British C olumbia Multiple Sclerosis, December 1, 2003; 9(6): 550 - 553. [Abstract] [PDF]
|
|
|
|
 |
|
 J Sastre-Garriga and X Montalban APS and the brain Lupus, December 1, 2003; 12(12): 877 - 882. [Abstract] [PDF]
|
|
|
|
|
|
S. Paus, A. Promse, S. Schmidt, T. Klockgether, Y. Mao-Draayer, and H. Panitch Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange Neurology, October 14, 2003; 61(7): 1022 - 1023. [Full Text] [PDF]
|
|
|
|
|
|
J de Seze, C Lebrun, T Stojkovic, D Ferriby, M Chatel, and P Vermersch Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis Multiple Sclerosis, October 1, 2003; 9(5): 521 - 525. [Abstract] [PDF]
|
|
|
|
|
|
R. Bergamaschi Glatiramer acetate treatment in Devic's neuromyelitis optica Brain, June 1, 2003; 126(6): E1 - E1. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Wingerchuk and B. G. Weinshenker Neuromyelitis optica: Clinical predictors of a relapsing course and survival Neurology, March 11, 2003; 60(5): 848 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Trebst, S. M. Staugaitis, P. Kivisakk, D. Mahad, M. K. Cathcart, B. Tucky, T. Wei, M. R. S. Rani, R. Horuk, K. D. Aldape, et al. CC Chemokine Receptor 8 in the Central Nervous System Is Associated with Phagocytic Macrophages Am. J. Pathol., February 1, 2003; 162(2): 427 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gold and C. Linington Devic's disease: bridging the gap between laboratory and clinic Brain, July 1, 2002; 125(7): 1425 - 1427. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||